Skip to main content
. 2019 Jun 12;14(6):e0217572. doi: 10.1371/journal.pone.0217572

Fig 1. A high level of lymphocytes in peripheral blood prior to MSC administration among GvHD patients who responded to therapy.

Fig 1

Blood samples were collected prior to therapy and blood count with differentials were examined. The lymphocyte level was higher in the responders. The difference between the groups is significant (P = 0.01) (a). Proportion of CD3 cells (P = 0.022) (b), proportion of CD19 cells (P = 0.64) (c) and proportion of CD56 cells (P = 0.01) (d) from total white blood cell (WBC) population as measured by flow cytometry.